Repligen (NASDAQ:RGEN) Stock Rating Upgraded by Zacks Research

Posted by on Aug 1st, 2026

Repligen (NASDAQ:RGEN – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

RGEN has been the subject of several other research reports. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price for the company. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Finally, Evercore reissued an “outperform” rating and set a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $166.43.

View Our Latest Stock Report on Repligen

Repligen Stock Performance

Repligen stock opened at $141.01 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.05. The stock has a fifty day moving average of $134.66 and a two-hundred day moving average of $131.60. The company has a market capitalization of $7.95 billion, a price-to-earnings ratio of 193.16, a PEG ratio of 2.67 and a beta of 1.06. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts anticipate that Repligen will post 2.06 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in the stock. Wasatch Advisors LP lifted its holdings in shares of Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Repligen by 11.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after purchasing an additional 2,332 shares in the last quarter. Everhart Financial Group Inc. purchased a new position in Repligen in the second quarter valued at about $303,000. Assenagon Asset Management S.A. purchased a new position in Repligen in the second quarter valued at about $9,687,000. Finally, Balefire LLC acquired a new position in shares of Repligen during the second quarter worth about $275,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Read More

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.